Tuesday, 17 November 2026 Every SEC filing alert, by company
ALFA USA Filings Every alert, straight from SEC EDGAR
News

IRulya Therapeutics Inc.

NASDAQ: IRLA · Life Sciences · 6 alerts · CIK 1662774

Share price
$37.36Close, Nov 16
Market cap
$405M
Shares outstanding
10.84MLatest SEC cover page
Sector
Life Sciences
Industry
Biological Products, (No Diagnostic Substances)SIC 2836

Today's reference numbers: shares from the company's latest SEC cover page, price from the latest market close. Not a valuation or a recommendation. All IRulya Therapeutics Inc. filings on SEC EDGAR ↗

4:31 PM ET 8-K
Financial Results

IRulya Therapeutics Financial Results

IRulya Therapeutics (formerly Quince Therapeutics) reported Q3 2026 financial results and provided a corporate update following its recent rebranding and leadership appointments. The company ended the quarter with $105.2 million in cash, which is expected to fund operations through 2028, supporting Phase 2 clinical readouts for its lead candidate LAM-001 in pulmonary diseases.

Term
Q3 2026

“This has been a transformative quarter for our company as we relaunched with a new name and sharpened focus on LAM-001, a potentially first in class inhaled formulation of rapamycin for serious pulmonary diseases. By targeting the mTOR pathway directly in the lungs, LAM-001 holds promise as a potentially disease modifying intervention designed to simultaneously minimize systemic exposure and side effects in these conditions. With a cash runway sufficient to deliver Phase 2 clinical results from multiple indications, we believe IRulya is in a great position to realize LAM-001’s potential.”

Brigette Roberts, M.D., Chief Executive Officer of IRulya Therapeutics
4:05 PM ET 10-Q
Financial Results

IRulya Therapeutics Q3 2026 Results: Net Loss of $27.7M, Loss Widens

IRulya Therapeutics Inc. significantly strengthened its liquidity position in the first nine months of 2026, with cash and short-term investments increasing to $105.2 million from $17.8 million at year-end 2025. The company underwent a major restructuring of its balance sheet, eliminating over $100 million in total liabilities and issuing Series C Preferred Stock valued at $143.8 million following the acquisition of Orphai Therapeutics.

Key figure
Net loss $27.7M
8:50 AM ET 8-K
Investor Presentation

IRulya Therapeutics Investor Presentation

IRulya Therapeutics Inc. (formerly Quince Therapeutics) has posted its updated Corporate Presentation for October 2026 to its website and filed it as an exhibit. The presentation provides a strategic overview of the company's product candidates, specifically LAM-001, and outlines planned clinical milestones and market opportunities in pulmonary hypertension and related lung diseases.

Get Alerts

Get ALFA Finder alerts first

Real-time SEC filing alerts for US stocks are launching soon. Leave your details and we'll tell you the moment they go live.